BIOHAVEN’S EXTENSIVE CLINICAL AND PRECLINICAL PROGRAMS
include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for antibody-mediated diseases; TRPM3 activation for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder; myostatin inhibition for neuromuscular and metabolic diseases, including obesity; and antibody recruiting, bispecific molecules and antibody drug conjugates for cancer.
EXPLORE OUR INTERACTIVE PIPELINE BELOW FOR MORE DETAILS
Obsessive-Compulsive Disorder
BHV-4157
Spinocerebellar Ataxia
BHV-4157
Spinal Muscular Atrophy
BHV-2000
Obesity
BHV-2000
Focal Epilepsy
BHV-7000
Generalized Epilepsy
BHV-7000
Bipolar Disorder
BHV-7000
Major Depressive Disorder
BHV-7000
Migraine
BHV-2100
Neuropathic Pain
BHV-2100
TYK2/JAK1 Inhibitor
(brain-penetrant)
Prevention of Amyloid Therapy Induced ARIA
BHV-8000
Early Alzheimer’s Disease
BHV-8000
Early Parkinson’s Disease
BHV-8000
Multiple Sclerosis
BHV-8000
IgG Degrader
Rheumatoid Arthritis
BHV-1300
Myasthenia Gravis
BHV-1310
IgA Degrader
IgA Nephropathy
BHV-1400
β1AR Autoantibody
Degrader
Dilated Cardiomyopathy
BHV-1600
Multiple Myeloma
BHV-1100
Advanced or Metastatic Epithelial Tumors
BHV-1510
Hodgkin’s Lymphoma
BHV-1500